Englewood, Colorado-based Paragon 28®, Inc. has added Scott Drake to its board of directors.
Scott Drake Joins Paragon 28’s Board of Directors
1 min read Premium comments
#paragon28Secondary#scottdrake
Drake has over 25 years of senior leadership experience in the global medical device industry. He has a proven track record of facilitating growth and creating shareholder value. He currently serves as chief executive officer and president of Oakwood Village, Ohio-based ViewRay, a medical technology company focused on MRI-guided radiation therapy. He has served on several boards for medical device companies. Drake is also co-founder of Louisville, Colorado-based Bolder Surgical.
Prior to ViewRay, Drake led Colorado Springs, Colorado-based The Spectranetics Corporation until Royal Philips acquired it in 2017. During his six years with Spectranetics, shareholder value increased from $170 million to $2.2 billion. From 2009 to 2011, Drake served as senior vice president, operations at Denver, Colorado-based DaVita, Inc., a company focused on kidney care, kidney disease, and dialysis. Drake also spent 17 years at Dublin, Ireland-based Covidien, plc where he worked in roles of increasing responsibility. He was global business unit president of the respiratory and monitoring solutions business and president of the surgery device business.
Drake said he was “Thrilled to join the board of directors at Paragon 28 in addressing the unmet and under-served needs of the foot and ankle community. Paragon has an impressive track record of growth fueled by an innovative and comprehensive suite of solutions.”
Drake continued, “I look forward to helping Paragon 28 achieve its growth agenda and mission of improving patient outcomes and lives.”
Founded in 2010, Paragon 28 is a privately held orthopedic medical device company. It is primarily focused on developing tools and solutions for the treatment of foot and ankle issues. According to its website, the company’s systems have supported 100,696 surgeries and it has filed 175 patents.
Paragon 28 Co-Founder, President, and Chief Executive Officer Albert DaCosta said about Drake, “Scott [Drake] is an accomplished leader in the medical technology space, possessing both outstanding strategic vision and operational know-how.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.